U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Development & Approval Process | Drugs
  4. How Drugs are Developed and Approved
  5. Drug and Biologic Approval and IND Activity Reports
  6. NDA and BLA Approvals
  7. Accelerated Approval Program
  8. Verified Clinical Benefit | Infectious Disease Accelerated Approvals Vaccines
  1. Accelerated Approval Program

Verified Clinical Benefit | Infectious Disease Accelerated Approvals Vaccines

This listing includes accelerated approvals (AAs) for infectious disease indications with postmarketing trials that have verified clinical benefit and for which traditional approval has been subsequently granted for the specific indication.

Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products. See Postmarket Requirements and Commitments for the status of specific requirements. 

Visit Accelerated Approvals for listings of ongoing, verified clinical benefit, and withdrawn infectious diseases and non-malignant hematological, neurological, and other disorder indications accelerated approvals.

Indications may remain on this page until FDA updates product labeling or publishes a Federal Register notice regarding a change in status. 

Total approval time was adjusted based on management decision. This is a legacy practice and is no longer exercised.

Drug Name Accelerated Approval Indication Accelerated Approval Date Traditional Approval Date
Bexsero (meningococcal group B vaccine) Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Meningococcal Group B Vaccine is approved for use in individuals 10 through 25 years of age 1/23/2015 8/19/2024
Bexsero (meningococcal group B vaccine) Active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Meningococcal Group B Vaccine is approved for use in individuals 10 through 25 years of age 1/23/2015 8/19/2024
Fluarix (influenza virus vaccine) For the prevention of influenza in adults 18 years and older 8/31/2005 10/2/2009
Afluria (influenza virus vaccine) For active immunization of adults 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine 9/28/2007 12/2/2011
Hiberix (haemophilus B conjugate vaccine (tetanus toxoid conjugate)) Active immunization for the prevention of invasive disease caused by Haemophilus influenzae type b 8/19/2009 4/30/2018
Agriflu (influenza virus vaccine) Active immunization of adults 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine 11/27/2009 10/29/2010
FluLaval; FluLaval Quadrivalent (influenza vaccine) Findicated for prevention of influenza in persons 3 to 8 years 6/9/2011 8/15/2013
Prevnar 13 (pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein)) To include the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F in persons 50 years of age or older  12/30/2011 5/22/2015
Fluzone High Dose (influenza vaccine) For prevention of influenze in adults 65 years of age and older 6/27/2012 10/31/2014
FluBlok (influenza vaccine) For active immunization against disease caused by influenza virus subtypes A and type B contained in the vaccine. Influenza vaccine is approved for use in persons  50 years of age and older  10/29/2014 10/7/2016
Trumenba (meningococcal group B vaccine) Active immunization to prevent invasive meningococcal disease caused by N. meningitidis serogroup B in individuals 10 through 25 years of age. 10/29/2014 3/13/2017
Trumenba (meningococcal group B vaccine) Two-dose schedule (a dose administered at 0 and 6 months) of Trumenba for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B   4/14/2016 11/19/2021
Flucelvax Quadrivalent (influenza vaccine) For prevention of influenza in persons 4 years to <18 years of age 5/23/2016 3/3/2021
Audenz (influenza a (H5N1) monovalent vaccine, adjuvanted) For active immunization of influenza in persons 6 months through 17 years of age 1/31/2020 11/17/2021
Back to Top